Major depressive disorder

InvestmentPitch Media Video Discusses New CSE Listing MindBio Therapeutics, Pioneering Clinical Studies of Micro-Dosing of Psychedelic Medicines

Retrieved on: 
Monday, May 8, 2023
National Alliance, Medicine, CSE, Depression, University, Canadian Securities Exchange, Suicide, Anxiety, LSD, National Alliance on Mental Illness, Patient, Mental disorder, Panic disorder, Therapy, Chronic pain, Mental health, Death, News, Micro, PTSD, Major depressive disorder, Pharmaceutical industry, Pharmacy

Based in Melbourne, Australia, MindBio Therapeutics is pioneering clinical studies into the micro-dosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions.

Key Points: 
  • Based in Melbourne, Australia, MindBio Therapeutics is pioneering clinical studies into the micro-dosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions.
  • A Media Snippet accompanying this announcement is available by clicking on the image or link below:
    For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • The video is available for viewing on “ InvestmentPitch ” and on “ YouTube ”.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter “MindBio Therapeutics” in the search box.

HMNC Brain Health Appoints Evan Papanastasiou as VP Clinical Development

Retrieved on: 
Monday, May 8, 2023
Lundbeck, PhD-MBA, MBA, Research, DSM-IV codes, Doctor of Philosophy, CNS, Boehringer Ingelheim, MDD, Patient, MD, Treatment-resistant depression, American College, TRD, Mental health, Major depressive disorder, Pharmaceutical industry, Nursing, Psychosis

MUNICH, Germany, May 08, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (‘‘HMNC’’ or the ‘‘Company’’), a global clinical-stage biopharmaceutical company, pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today the appointment of Dr. Evan Papanastasiou, MD MSc PhD MBA, as VP Clinical Development, to lead pre-clinical and clinical programs and support new development opportunities at the Company.

Key Points: 
  • MUNICH, Germany, May 08, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (‘‘HMNC’’ or the ‘‘Company’’), a global clinical-stage biopharmaceutical company, pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today the appointment of Dr. Evan Papanastasiou, MD MSc PhD MBA, as VP Clinical Development, to lead pre-clinical and clinical programs and support new development opportunities at the Company.
  • In his new role, Dr. Papanastasiou will be responsible for the strategy, direction, and execution of the Company’s clinical development plans, such as progressing HMNC Brain Health’s Ketabon program towards the pathway of commercialization.
  • Most recently, Dr. Papanastasiou served as the Global Clinical Program Leader at Boehringer Ingelheim, where he was responsible for the ongoing refinement of clinical development pathways; coordination of scientific & cross-functional teams in a matrix environment.
  • “I am looking forward to joining the clinical leadership team at HMNC Brain Health as they are disruptors in the mental health industry and personalizing treatments that benefit individual patients rather than serving the one-size-fits-all current standard of mental health treatment.

ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder

Retrieved on: 
Thursday, May 4, 2023
Patent, Major depressive disorder, Norepinephrine transporter, United States patent law, NET, Patent Cooperation Treaty, EOP, Phase II, CNS, PCT, Norepinephrine, MDD, Ophthalmology, European, FDA, Treatment, Pharmaceutical industry

FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it received a US patent certificate, US 11,554,154 B2, for PDC-1421, for the treatment of Major Depressive Disorder (MDD) on April 25, 2023.

Key Points: 
  • FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it received a US patent certificate, US 11,554,154 B2, for PDC-1421, for the treatment of Major Depressive Disorder (MDD) on April 25, 2023.
  • The patent application was submitted to the US Patent and Trademark Office (USPTO) on July 22, 2020, under the title of “Polygala Extract for the Treatment of Major Depressive Disorder.” The invention relates to a method for treating Major Depressive Disorder by orally administering a composition containing a Radix Polygalae (Polygala tenuifolia Willd.)
  • PDC-1421 is a drug product of ABV-1504 that can be prepared into a gelatin capsule for oral administration.
  • The patent was also submitted for Patent Cooperation Treaty (PCT) and subsequently filed in several countries, including the European Union, China, Japan in 2022.

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Retrieved on: 
Wednesday, May 3, 2023
Chief scientific officer, CINP, EDT, Congress, MDD, Patient, Queen Elizabeth Hotel, Poster, Safety, Major depressive disorder, Pharmaceutical industry

LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce that Dr. Carol Routledge, Chief Medical and Scientific Officer, will deliver a poster presentation at the 34th CINP World Congress of Neuropsychopharmacology in Montreal, Canada which is taking place on May 7-10, 2023.

Key Points: 
  • LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce that Dr. Carol Routledge, Chief Medical and Scientific Officer, will deliver a poster presentation at the 34th CINP World Congress of Neuropsychopharmacology in Montreal, Canada which is taking place on May 7-10, 2023.
  • The poster will showcase positive data from the Company’s Phase IIa trial of SPL026, the first placebo-controlled study of a short-duration psychedelic for the treatment of Major Depressive Disorder (“MDD”).
  • The trial investigated the efficacy, safety and tolerability of a 21.5mg intravenous dose of SPL026, a proprietary synthetic formulation of N,N-Dimethyltryptamine (“DMT”), with supportive therapy in 34 patients with moderate/severe MDD.
  • Time: 10:15 – 10:45 a.m. and 4:00 – 4:30 p.m. (EDT)
    Location: Level 2 Foyer, Fairmont The Queen Elizabeth Hotel, Montreal, Quebec, Canada

RLMD INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD

Retrieved on: 
Monday, May 1, 2023
Class Action Lawsuit, Professional Services, Legal, Titan, Depression, MADRS, MDD, Advertising, News, I-Space (Chinese company), Major depressive disorder, Pharmaceutical industry, Cryptocurrency

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=15724 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.

Retrieved on: 
Monday, May 1, 2023
Depression, Telephone, MADRS, Levi, MDD, News, NYSE, Major depressive disorder, Pharmaceutical industry, Cryptocurrency

New York, New York--(Newsfile Corp. - May 1, 2023) - Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NYSE: RLMD) concerning possible violations of federal securities laws.

Key Points: 
  • New York, New York--(Newsfile Corp. - May 1, 2023) - Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NYSE: RLMD) concerning possible violations of federal securities laws.
  • Specifically, the REL-1017 treatment showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for placebo, a higher-than-expected placebo response.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Neuronetics Announces Expanded TMS Access through United HealthCare

Retrieved on: 
Friday, April 28, 2023
Major depressive disorder, Network, Marketing, TMS, RI, NGS, Policy, Mental health, Quality of life, ME, Health policy, Government, Medicare, STIM, Neuronetics, UnitedHealth Group, MDD, Patient, Practitioner, Health, Health insurance

This policy expansion increases access for patients to the Company’s NeuroStar® Advanced Therapy for Mental Health by adopting the recently announced NGS Medicare criteria allowing non-physician practitioners (NPPs), like nurse practitioners, to order and administer TMS Therapy to their patients with major depressive disorder (MDD) in states where they have scope of practice to do so.

Key Points: 
  • This policy expansion increases access for patients to the Company’s NeuroStar® Advanced Therapy for Mental Health by adopting the recently announced NGS Medicare criteria allowing non-physician practitioners (NPPs), like nurse practitioners, to order and administer TMS Therapy to their patients with major depressive disorder (MDD) in states where they have scope of practice to do so.
  • United HealthCare Medicare Advantage plans implementing the National Government Services criteria include 434,262 covered lives in CT, MA, ME, MN, NH, NY, RI, and VT.
    Neuronetics previously announced updates to United HealthCare Optum’s commercial policy that expands TMS access for over 23 million covered lives.
  • Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payers to advocate for health policy changes.
  • For more information about NeuroStar TMS Therapy, please visit NeuroStar.com .

RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.

Retrieved on: 
Wednesday, April 26, 2023
Depression, Telephone, MADRS, Levi, MDD, News, NYSE, Major depressive disorder, Pharmaceutical industry, Cryptocurrency

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NYSE: RLMD) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NYSE: RLMD) concerning possible violations of federal securities laws.
  • Before market opened on October 13, 2022, Relmada announced the results of its RELIANCE III study (REL-1017-303), evaluating the drug REL-1017 as a monotherapy for Major Depressive Disorder (MDD).
  • Specifically, the REL-1017 treatment showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for placebo, a higher-than-expected placebo response.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.

Altasciences Completes Clinical Portion of Alzamend Neuro’s Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer’s

Retrieved on: 
Tuesday, April 18, 2023
Mental Health, Neurology, Consulting, Clinical Trials, Professional Services, Biotechnology, Managed Care, Health, Pharmaceutical, PK, Major depressive disorder, Partnership, Drug development, Clinical trial, Pharmacokinetics, Dementia, MDD, Patient, Post-traumatic stress disorder, MAD, Biostatistics, Bipolar disorder, PTSD, Safety, Pharmaceutical industry

Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer’s disease (Alzheimer’s).

Key Points: 
  • Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer’s disease (Alzheimer’s).
  • In addition to having conducted Alzamend’s Phase IIa multiple ascending dose (MAD) clinical trial in healthy subjects, Altasciences is continuing to provide clinical monitoring, project management, biostatistics, pharmacokinetics (PK), bioanalysis, and medical writing solutions as the product candidate is evaluated in Alzheimer’s patients.
  • “Our Phase I study was successfully conducted with Altasciences and we are excited to continue this partnership with our Phase IIa MAD study,” said Stephan Jackman, Chief Executive Officer of Alzamend.
  • “Altasciences’ mission is to help sponsors bring promising novel treatments, like AL001, to the people who need them, faster,” says Marie-Hélène Raigneau, Co-chief Operating Officer.

Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy

Retrieved on: 
Thursday, April 13, 2023
Major depressive disorder, Marketing, TMS, Blue Cross Blue Shield Association, BCBS, Policy, Mental health, Quality of life, Health policy, STIM, Neuronetics, Medicare, MDD, Patient, Practitioner, Transcranial magnetic stimulation, Pharmaceutical industry, Nursing, Health insurance

This policy change increases access for patients to the Company’s NeuroStar® Advanced Therapy for Mental Health.

Key Points: 
  • This policy change increases access for patients to the Company’s NeuroStar® Advanced Therapy for Mental Health.
  • An additional update in the revised policy is a lower medication requirement – reduced from four failed medications to two prior to TMS treatment.
  • The BCBS policy update builds on recent momentum from health payers to expand coverage to TMS Therapy.
  • Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payers to advocate for health policy changes.